The top 10 biopharma stock gainers and losers for the week of Oct. 28–Nov. 1, 2019.

All of the biopharma stocks tracked by BioWorld, including their weekly and year-to-date percent changes and weekly trading volumes.

Significant progress is being made in the development of next-generation treatments for multiple myeloma. For that reason, investors and industry analysts alike will be anxiously awaiting the abstracts for the upcoming American Society of Hematology (ASH) annual meeting.

Total raised in public, private and other financings of biotech companies, comparing 2019 vs. 2018.

There has been a flurry of news flowing from companies developing new antibiotics during the month and the BioWorld Infectious Diseases index, after languishing for the past several months, is tracking up 5% for October. The activity comes against the backdrop of the completion of the AMR Challenge.

Year-to-date money raised in public, private and other financings of biopharma companies.

Arcutis Biotherapeutics Inc. completed a $94.5 million series C financing round.

"We believe there is a large patient population that is underserved right now. T cell-targeting therapies, to be honest, are great. Look at the clinical data with PD-1s. They're fantastic for patients, but T-cell infiltration in all human cancer is only 25 percent."

The FDA released final guidance to help sponsors develop systemic drugs for HIV-1 pre-exposure prophylaxis (PrEP). The guidance provides nonclinical and clinical recommendations, with a focus on long-acting systemic drugs intended to prevent sexually acquired infections.

Grants received by biopharma companies, July 1 - October 24, 2019